Abstract
Osimertinib is an oral, central nervous system-active, EGFR tyrosine kinase inhibitor (TKI) for the treatment of EGFR T790M-positive advanced NSCLC. Here we have evaluated EGFR mutation frequencies in two phase II studies of osimertinib (AURA extension and AURA2). After progression while receiving their latest line of therapy, patients with EGFR mutation-positive advanced NSCLC provided tumor samples for mandatory central T790M testing for the study selection criteria. Tumor tissue mutation analysis for patient selection was performed with the Roche cobas EGFR Mutation Test (European Conformity-in vitro diagnostic, labeled investigational use only) (Roche Molecular Systems, Pleasanton, CA). Patients should not have been prescreened for T790M mutation status. The cobas test results were compared with those of the MiSeq next-generation sequencing system (Illumina, San Diego, CA), which was used as a reference method. Samples from 324 and 373 patients screened for AURA extension and AURA2, respectively, produced valid cobas test results. The T790M detection rates were similar between AURA extension and AURA2 (64% and 63%, respectively). The pooled T790M rate was 63%, with no difference by ethnicity (63% for Asian and non-Asian pat...Continue Reading
References
Mar 3, 2005·Journal of the National Cancer Institute·Hisayuki ShigematsuAdi F Gazdar
Jul 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David M JackmanPasi A Jänne
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Jan 21, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria E ArcilaMarc Ladanyi
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vicki Leigh KeedyGiuseppe Giaccone
Jul 22, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey R OxnardWilliam Pao
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Mar 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helena A YuGregory J Riely
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Sep 17, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jong-Mu SunKeunchil Park
Jan 21, 2014·The Lancet Oncology·Yi-Long WuSarayut L Geater
Apr 2, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Wei LiGerald Schmid-Bindert
Apr 29, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J L KuiperE F Smit
Jun 5, 2014·Cancer Discovery·Darren A E CrossWilliam Pao
Aug 15, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jean-Yves DouillardRose McCormack
Sep 16, 2014·PloS One·Yaxiong ZhangLi Zhang
Apr 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chee Khoon LeeJames Chih-Hsin Yang
Apr 30, 2015·The New England Journal of Medicine·Pasi A JänneMalcolm Ranson
Feb 11, 2016·Oncotarget·Shang-Gin WuJin-Yuan Shih
May 24, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Konstantinos LeventakosAaron S Mansfield
Jun 21, 2016·Cancer Science·Yoshihisa Kobayashi, Tetsuya Mitsudomi
Jul 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter BallardDarren Cross
Jul 29, 2016·OncoTargets and Therapy·Dan ChenGuoping Cheng
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S NovelloUNKNOWN ESMO Guidelines Committee
Dec 14, 2016·The New England Journal of Medicine·Tony S MokUNKNOWN AURA3 Investigators
Feb 22, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James Chih-Hsin YangPasi A Jänne
Apr 22, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Suzanne JenkinsGlenwood D Goss
Citations
Aug 3, 2019·Future Oncology·Maximilian J HochmairTanja Cufer
Aug 28, 2019·Future Oncology·Nicolas Girard
Oct 5, 2019·Current Medical Research and Opinion·Byoung Chul ChoSang-We Kim
Dec 22, 2019·Advances in Therapy·Nobuyuki YamamotoMaximilian J Hochmair
Feb 23, 2019·Journal of Translational Medicine·Wenxian WangZhengbo Song
Aug 8, 2020·Future Oncology·Bruce FeinbergMaximillian J Hochmair
Jul 23, 2020·Targeted Oncology·Chi-Lu ChiangChao-Hua Chiu
Dec 1, 2018·Oncology and Therapy·Takashi SetoHideo Saka
Sep 8, 2018·Scientific Reports·Francesco PassigliaAntonio Russo
Aug 28, 2018·Internal Medicine·Shingo NasuTomonori Hirashima
Aug 15, 2018·Diagnostic Pathology·Chenguang LiChangli Wang
Nov 27, 2019·Cancer·Vassiliki A PapadimitrakopoulouTony Mok
Sep 16, 2020·Future Oncology·Hai-Yan Tu, Yi-Long Wu
Jun 23, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·R Donald HarveyPatrick Medina
Oct 30, 2020·Cancers·Elisa GobbiniPierre Saintigny
Aug 24, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jhanelle E GraySuresh S Ramalingam
Oct 1, 2019·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ana C Z GelattiFernando C Santini
Feb 6, 2020·Clinical Lung Cancer·Riyaz Shah, Jason F Lester
Oct 15, 2020·Investigational New Drugs·Jin-Ji YangYi-Long Wu
Apr 16, 2021·Future Oncology·Edward S KimJames C-H Yang
Apr 17, 2021·Clinical Drug Investigation·Hai-Yan TuYi-Long Wu
Jul 3, 2021·Cancers·Giannis MountziosKonstantinos N Syrigos
Aug 31, 2021·Critical Reviews in Oncology/hematology·Gabriel Fernando TorresAndrés F Cardona